ArticleBreast cancer research and treatment2026
Adenoid cystic carcinoma of the breast: a case series of 26 patients.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough triple-negative, adenoid cystic carcinoma of the breast (ACCB) is an uncommon, slow-growing malignancy with a favorable prognosis. There are no treatment standards or therapeutic consensus because of its scarcity.
methodsData on 26 patients with ACCB from two distinct French cancer centers were presented in this study. Clinical, histological and molecular features of these carcinomas were described. Therapeutic management and patient follow-up was also reported.
resultsThe median age of this cohort was 59 years [22-82] and the median follow-up was 4.2 years [0.5-23.9]. The most represented stages were IA (45.5%) and IIA (31.8%), with T1-T2 representing nineteen cases (86.3%). Four patients had axillary node metastases. Only 3 tumors were ER or PR positive. All tumors were HER-2 negative. Nine patients had a rearrangement of the MYB gene. Twenty-five patients had initial surgery. Adjuvant chemotherapy was administered to three patient. Twenty patients received adjuvant radiotherapy. At last follow-up, five of the patients had died from complications of the disease.
conclusionAlthough ACCB generally has a good prognosis, the treatment of this rare type of breast cancer remains challenging to ensure favorable outcomes with minimal sequelae. Initial staging and long-term follow-up using appropriate imaging modalities are essential for selecting tailored treatment strategies and detecting early relapses.
Indexed as
Identifiers
42283891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.